user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 427778 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.

Regeneron Pharmaceuticals Up 0.8% Since Brean Capital Downgraded One Week Ago (REGN)

Published on Thu, 01/24/2013 - 10:09
By Robert Cotter

Regeneron Pharmaceuticals was downgraded from Buy to Hold by Brean Capital one week ago. Regeneron Pharmaceuticals shares are selling at $176.16, 0.8% above the $174.84 price point of one week ago.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

Regeneron Pharmaceuticals has overhead space with shares priced $176.30, or 3.2% below the average consensus analyst price target of $182.08. The stock should find initial support at its 50-day moving average (MA) of $173.36 and further support at its 200-day MA of $144.73.

In the past 52 weeks, shares of Regeneron Pharmaceuticals have traded between a low of $42.83 and a high of $188.95 and are now at $176.30, which is 312% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.9% while the 200-day MA has risen 0.4%.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

TD Securities Made the Right Call, Pan A...

Pan American Silver was downgraded from Buy to Hold by TD Securities one week ago. The ...

Analyst Rating In Review: Medivation Bid...

One week ago Medivation (NASDAQ:MDVN) was downgraded from Buy to Neutral at Goldman Sac ...

Auxilium Pharmaceuticals In Retrospect: ...

RBC Capital downgraded Auxilium Pharmaceuticals (NASDAQ:AUXL) from Outperform to Sector ...

Analyst Rating In Review: Marvell Techno...

A week ago, JMP Securities upgraded Marvell Technology from Underperform to Market Perf ...

Buffalo Wild Wings Fulfills the Promise:...

A week ago, Miller Tabak upgraded Buffalo Wild Wings from Hold to Buy. Buffalo Wild Wi ...

Ericsson Down 1.6% Since UBS Downgraded ...

UBS downgraded Ericsson (NASDAQ:ERIC) from Buy to Neutral a week ago. The shares close ...

Analyst Rating Flashback: SYNNEX Up 8.1%...

Raymond James upgraded SYNNEX (NYSE:SNX) from Market Perform to Outperform a week ago. ...

Freeport-McMoRan In Retrospect: Shares D...

A week ago, Tigress Financial downgraded Freeport-McMoRan from Strong Buy to Neutral. ...

Most Popular Video News